The COVID-19 pandemic has had widespread effects across the globe, and its causative
agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to end …

An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and …

Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
present a promising approach to combat the coronavirus disease 2019 (COVID…

Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Background Transthyretin amyloidosis, also called ATTR amyloidosis, is a life-threatening
disease characterized by progressive accumulation of misfolded transthyretin (TTR) protein in …

BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that encodes the
SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has …

The SARS-CoV-2 spike (S) protein variant D614G supplanted the ancestral virus worldwide,
reaching near fixation in a matter of months. Here we show that D614G was more infectious …

Neutralizing antibodies have become an important tool in treating infectious diseases.
Recently, two separate approaches yielded successful antibody treatments for Ebola—one from …

Background Recent data suggest that complications and death from coronavirus disease
2019 (Covid-19) may be related to high viral loads. Methods In this ongoing, double-blind, …

Background REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal
antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of …